Division of Gastroenterology, Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada.
Department of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Can J Gastroenterol Hepatol. 2017;2017:2696947. doi: 10.1155/2017/2696947. Epub 2017 Nov 23.
The inpatient status is a well-known risk factor for incomplete video capsule endoscopy (VCE) examinations due to prolonged transit time. We aimed to evaluate the effect of prucalopride on small bowel transit time for hospitalized patients undergoing VCE.
We included all hospitalized patients who underwent VCE at a tertiary academic center from October 2011 through September 2016. A single 2 mg dose of prucalopride was given exclusively for all patients who underwent VCE between March 2014 and December 2015. VCE studies were excluded if the capsule was retained or endoscopically placed, if other prokinetic agents were given, in cases with technical failure, or if patients had prior gastric or small bowel resection.
442 VCE were identified, of which 68 were performed in hospitalized patients. 54 inpatients were included, of which 29 consecutive patients received prucalopride. The prucalopride group had a significantly shorter small bowel transit time compared to the control group (92 versus 275.5, < 0.001). There was a trend for a higher completion rate in the prucalopride group (93.1% versus 76%, = 0.12).
Our results suggest that the administration of prucalopride prior to VCE is a simple and effective intervention to decrease small bowel transit time.
由于传输时间延长，住院状态是导致胶囊内镜（VCE）检查不完整的一个众所周知的危险因素。我们旨在评估普芦卡必利对接受 VCE 的住院患者小肠传输时间的影响。
我们纳入了 2011 年 10 月至 2016 年 9 月在一家三级学术中心接受 VCE 的所有住院患者。2014 年 3 月至 2015 年 12 月期间，所有接受 VCE 的患者均单独给予 2mg 剂量的普芦卡必利。如果胶囊被保留或在内镜下放置、给予了其他促动力药物、出现技术故障或患者有既往胃或小肠切除术，则排除 VCE 研究。
共纳入 442 例 VCE，其中 68 例在住院患者中进行。纳入 54 例住院患者，其中 29 例连续患者接受了普芦卡必利治疗。与对照组相比，普芦卡必利组的小肠传输时间明显更短（92 比 275.5，<0.001）。普芦卡必利组的完成率有升高的趋势（93.1%比 76%，=0.12）。
我们的结果表明，在 VCE 之前给予普芦卡必利是一种简单有效的干预措施，可缩短小肠传输时间。
